"Antibodies, Neutralizing" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Antibodies that reduce or abolish some biological activity of a soluble antigen or infectious agent, usually a virus.
| Descriptor ID |
D057134
|
| MeSH Number(s) |
D12.776.124.486.485.114.244 D12.776.124.790.651.114.244 D12.776.377.715.548.114.244
|
| Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Antibodies, Neutralizing".
Below are MeSH descriptors whose meaning is more specific than "Antibodies, Neutralizing".
This graph shows the total number of publications written about "Antibodies, Neutralizing" by people in this website by year, and whether "Antibodies, Neutralizing" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2009 | 1 | 2 | 3 |
| 2010 | 2 | 9 | 11 |
| 2011 | 2 | 7 | 9 |
| 2012 | 6 | 8 | 14 |
| 2013 | 4 | 10 | 14 |
| 2014 | 7 | 11 | 18 |
| 2015 | 12 | 5 | 17 |
| 2016 | 11 | 14 | 25 |
| 2017 | 9 | 14 | 23 |
| 2018 | 16 | 11 | 27 |
| 2019 | 13 | 7 | 20 |
| 2020 | 20 | 18 | 38 |
| 2021 | 18 | 22 | 40 |
| 2022 | 6 | 37 | 43 |
| 2023 | 2 | 36 | 38 |
| 2024 | 12 | 11 | 23 |
To return to the timeline,
click here.
Below are the most recent publications written about "Antibodies, Neutralizing" by people in Profiles.
-
SARS-CoV-2 XBB.1.5 mRNA booster vaccination elicits limited mucosal immunity. Sci Transl Med. 2024 Oct 23; 16(770):eadp8920.
-
Determination of T cell response against XBB variants in adults who received either monovalent wild-type inactivated whole virus or mRNA vaccine or bivalent WT/BA.4-5 COVID-19 mRNA vaccine as the additional booster. Int J Infect Dis. 2024 Dec; 149:107271.
-
Discovery and characterization of a pan-betacoronavirus S2-binding antibody. Structure. 2024 Nov 07; 32(11):1893-1909.e11.
-
Recurrent SARS-CoV-2 spike mutations confer growth advantages to select JN.1 sublineages. Emerg Microbes Infect. 2024 Dec; 13(1):2402880.
-
Omicron COVID-19 immune correlates analysis of a third dose of mRNA-1273 in the COVE trial. Nat Commun. 2024 Sep 11; 15(1):7954.
-
Optimal Humanized Scg3-Neutralizing Antibodies for Anti-Angiogenic Therapy of Diabetic Retinopathy. Int J Mol Sci. 2024 Sep 01; 25(17).
-
Administration of anti-HIV-1 broadly neutralizing monoclonal antibodies with increased affinity to Fc? receptors during acute SHIVAD8-EO infection. Nat Commun. 2024 Aug 29; 15(1):7461.
-
Robust SARS-CoV-2-neutralizing antibodies sustained through 6?months post XBB.1.5 mRNA vaccine booster. Cell Rep Med. 2024 Sep 17; 5(9):101701.
-
Bivalent Omicron BA.4/BA.5 BNT162b2 Vaccine in 6-Month- to <12-Year-Olds. J Pediatric Infect Dis Soc. 2024 Aug 24; 13(8):421-429.
-
Potent neutralizing human monoclonal antibodies protect from Rift Valley fever encephalitis. JCI Insight. 2024 Aug 01; 9(18).